• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV 感染者中非酒精性脂肪性肝病患者的不良心血管结局风险。

Risk of adverse cardiovascular outcomes among people with HIV and nonalcoholic fatty liver disease.

机构信息

Section of Gastroenterology and Hepatology, West Virginia University School of Medicine, Morgantown, West Virginia.

Department of Gastroenterology, Hepatology and Nutrition.

出版信息

AIDS. 2023 Jul 1;37(8):1209-1216. doi: 10.1097/QAD.0000000000003537. Epub 2023 Mar 3.

DOI:10.1097/QAD.0000000000003537
PMID:36928107
Abstract

OBJECTIVE

To examine and compare the risk of major adverse cardiovascular events (MACEs) between people with HIV (PWH) with and without nonalcoholic fatty liver disease (NAFLD).

DESIGN

Population-based, multicenter, retrospective cohort study.

METHODS

Data on PWH between January 1, 2008, and December 31, 2020 were extracted from the TriNetX database. Primary outcomes were defined as the first incidence of myocardial infarction (MI), MACE, new-onset heart failure (HF), and a composite of cerebrovascular disease. Cox models were used to obtain hazard ratios (HRs) and 95% confidence intervals (CIs).

RESULTS

A total of 151 868 patients were identified as having HIV. After exclusions, 4969 patients were identified as having NAFLD. Of them, 4463 (90%) were propensity matched to a non-NAFLD control. Patients with NAFLD were older (42.9 versus 40.8 years). Among the NAFLD cohort, most participants were male and had a smoking history (12.3 versus 9.8%) than non-NAFLD. The mean follow-up was 4.8 ± 1.1 years for the NAFLD group and 5.3 ± 1.2 years for the non-NAFLD group. The risk of all outcomes was statistically significantly higher in NAFLD patients compared to those without NAFLD: MI (HR, 1.49; 95% CI, 1.11-2.01) MACE (HR, 1.49; 95% CI, 1.25-1.79), HF (HR, 1.73; 95% CI 1.37-2.19) and, cerebrovascular diseases (HR, 1.25; 95% CI, 1.05-1.48) and sensitivity analysis showed similar magnitude to the one generated in the primary analysis.

CONCLUSIONS

Patients with NAFLD have an elevated risk of adverse cardiovascular events (CVEs). The results indicate the need for targeted efforts to improve awareness of risks factors associated with adverse CVEs risk in PWH with NAFLD.

摘要

目的

研究并比较合并与不合并非酒精性脂肪性肝病(NAFLD)的 HIV 感染者(PWH)发生主要不良心血管事件(MACE)的风险。

设计

基于人群的、多中心、回顾性队列研究。

方法

从 TriNetX 数据库中提取 2008 年 1 月 1 日至 2020 年 12 月 31 日期间的 PWH 数据。主要结局定义为首次发生心肌梗死(MI)、MACE、新发心力衰竭(HF)以及脑血管疾病的复合结局。采用 Cox 模型获得风险比(HR)和 95%置信区间(CI)。

结果

共纳入 151868 例 HIV 感染者,排除后,有 4969 例患者被诊断为 NAFLD,其中 4463 例(90%)按倾向评分匹配了非 NAFLD 对照组。NAFLD 组患者年龄较大(42.9 岁比 40.8 岁)。在 NAFLD 队列中,与非 NAFLD 组相比,大多数患者为男性且有吸烟史(12.3%比 9.8%)。NAFLD 组的平均随访时间为 4.8±1.1 年,非 NAFLD 组为 5.3±1.2 年。与非 NAFLD 患者相比,NAFLD 患者发生所有结局的风险均显著更高:MI(HR,1.49;95%CI,1.11-2.01)、MACE(HR,1.49;95%CI,1.25-1.79)、HF(HR,1.73;95%CI,1.37-2.19)和脑血管疾病(HR,1.25;95%CI,1.05-1.48)。敏感性分析得出的结果与主要分析相似。

结论

合并 NAFLD 的 PWH 发生不良心血管事件(CVE)的风险增加。结果表明,需要有针对性地努力提高对 PWH 合并 NAFLD 相关不良 CVE 风险因素的认识。

相似文献

1
Risk of adverse cardiovascular outcomes among people with HIV and nonalcoholic fatty liver disease.HIV 感染者中非酒精性脂肪性肝病患者的不良心血管结局风险。
AIDS. 2023 Jul 1;37(8):1209-1216. doi: 10.1097/QAD.0000000000003537. Epub 2023 Mar 3.
2
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.在非酒精性脂肪性肝病(NAFLD)合并2型糖尿病患者中,胰高血糖素样肽-1(GLP-1)受体激动剂与其他降糖药物的心血管及死亡率结局:一项基于人群的大型匹配队列研究
Diabetologia. 2024 Mar;67(3):483-493. doi: 10.1007/s00125-023-06057-5. Epub 2023 Dec 20.
3
Cardiovascular Outcomes and Mortality After Bariatric Surgery in Patients With Nonalcoholic Fatty Liver Disease and Obesity.肥胖症合并非酒精性脂肪性肝病患者行减重手术后的心血管结局和死亡率。
JAMA Netw Open. 2023 Apr 3;6(4):e237188. doi: 10.1001/jamanetworkopen.2023.7188.
4
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.SGLT-2i 和 GLP-1RA 治疗在不同非酒精性脂肪性肝病状态的 2 型糖尿病患者中的结局。
JAMA Netw Open. 2023 Dec 1;6(12):e2349856. doi: 10.1001/jamanetworkopen.2023.49856.
5
Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.非酒精性脂肪性肝病和纤维化与前瞻性研究中心血管事件风险增加相关。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2324-2331.e4. doi: 10.1016/j.cgh.2019.12.026. Epub 2019 Dec 27.
6
Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.非酒精性脂肪性肝病和非酒精性脂肪性肝炎伴肝纤维化对 HIV 感染者新发糖尿病的预测作用:一项纵向队列研究。
Clin Infect Dis. 2023 Dec 15;77(12):1687-1695. doi: 10.1093/cid/ciad433.
7
Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Community-Based Cohort Study.非酒精性脂肪肝疾病的严重程度与高血压前期或高血压患者的心血管结局相关:一项基于社区的队列研究。
Front Endocrinol (Lausanne). 2022 Aug 25;13:942647. doi: 10.3389/fendo.2022.942647. eCollection 2022.
8
Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study.非酒精性脂肪性肝病(NAFLD)、代谢综合征与心房颤动中的心血管事件。一项前瞻性多中心队列研究。
Intern Emerg Med. 2021 Nov;16(8):2063-2068. doi: 10.1007/s11739-021-02682-3. Epub 2021 Mar 13.
9
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.非酒精性脂肪性肝病与主要不良心血管事件的发生:一项全国性组织学队列研究结果
Gut. 2022 Sep;71(9):1867-1875. doi: 10.1136/gutjnl-2021-325724. Epub 2021 Sep 6.
10
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults.非酒精性脂肪性肝病与急性心肌梗死和卒中发病风险的关系:来自 1800 万欧洲成年人匹配队列研究的结果。
BMJ. 2019 Oct 8;367:l5367. doi: 10.1136/bmj.l5367.

引用本文的文献

1
Proton pump inhibitors and all-cause mortality in colorectal cancer.质子泵抑制剂与结直肠癌的全因死亡率
Sci Rep. 2025 Jul 1;15(1):21315. doi: 10.1038/s41598-025-05570-4.
2
Adverse Liver and Renal Outcomes After Initiating SGLT-2i and GLP-1RA Therapy Among Patients With Diabetes and MASLD.糖尿病和非酒精性脂肪性肝病患者启动SGLT-2抑制剂和GLP-1受体激动剂治疗后的肝脏和肾脏不良结局
J Diabetes. 2025 Apr;17(4):e70069. doi: 10.1111/1753-0407.70069.
3
Distinct metabolic perturbations link liver steatosis and incident CVD in lean but not obese PWH.
在瘦的(而非肥胖的)艾滋病病毒感染者中,不同的代谢紊乱将肝脂肪变性与心血管疾病的发生联系起来。
BMC Med. 2025 Feb 11;23(1):78. doi: 10.1186/s12916-025-03914-5.
4
Proton pump inhibitors and all-cause mortality risk among cancer patients.质子泵抑制剂与癌症患者的全因死亡风险
World J Clin Oncol. 2025 Jan 24;16(1):99240. doi: 10.5306/wjco.v16.i1.99240.
5
Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.优化人类免疫缺陷病毒感染者的心血管代谢风险:深入探究一种重要的风险增强因素。
Am J Prev Cardiol. 2024 Oct 28;20:100888. doi: 10.1016/j.ajpc.2024.100888. eCollection 2024 Dec.
6
Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV.在一个大型 HIV 感染者队列中,肝脂肪变性和肝纤维化的负担。
HIV Med. 2024 Dec;25(12):1308-1324. doi: 10.1111/hiv.13730. Epub 2024 Nov 7.
7
MASLD in persons with HIV is associated with high cardiometabolic risk as evidenced by altered advanced lipoprotein profiles and targeted metabolomics.HIV 感染者中的代谢相关性脂肪性肝病与心血管代谢风险升高相关,这可通过改变的先进脂蛋白谱和靶向代谢组学来证明。
Lipids Health Dis. 2024 Oct 17;23(1):339. doi: 10.1186/s12944-024-02317-4.
8
Liver Steatosis is Prevalent in Lean People With HIV and Associated With Exposure to Antiretroviral Treatment-A Cross-sectional Study.肝脏脂肪变性在瘦的HIV感染者中普遍存在且与抗逆转录病毒治疗暴露相关——一项横断面研究
Open Forum Infect Dis. 2024 May 7;11(6):ofae266. doi: 10.1093/ofid/ofae266. eCollection 2024 Jun.
9
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.在非酒精性脂肪性肝病(NAFLD)合并2型糖尿病患者中,胰高血糖素样肽-1(GLP-1)受体激动剂与其他降糖药物的心血管及死亡率结局:一项基于人群的大型匹配队列研究
Diabetologia. 2024 Mar;67(3):483-493. doi: 10.1007/s00125-023-06057-5. Epub 2023 Dec 20.
10
Cardiovascular Outcomes Among Persons with HIV and Nonalcoholic Fatty Liver Disease.感染艾滋病毒且患有非酒精性脂肪性肝病者的心血管结局
AIDS. 2023 Jul;37(8):1329-1331. doi: 10.1097/QAD.0000000000003562.